These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26364847)

  • 1. Deletions in a ribosomal protein-coding gene are associated with tigecycline resistance in Enterococcus faecium.
    Niebel M; Quick J; Prieto AM; Hill RL; Pike R; Huber D; David M; Hornsey M; Wareham D; Oppenheim B; Woodford N; van Schaik W; Loman N
    Int J Antimicrob Agents; 2015 Nov; 46(5):572-5. PubMed ID: 26364847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic analysis of reduced susceptibility to tigecycline in Enterococcus faecium.
    Cattoir V; Isnard C; Cosquer T; Odhiambo A; Bucquet F; Guérin F; Giard JC
    Antimicrob Agents Chemother; 2015 Jan; 59(1):239-44. PubMed ID: 25348531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tigecycline resistance in clinical isolates of Enterococcus faecium is mediated by an upregulation of plasmid-encoded tetracycline determinants tet(L) and tet(M).
    Fiedler S; Bender JK; Klare I; Halbedel S; Grohmann E; Szewzyk U; Werner G
    J Antimicrob Chemother; 2016 Apr; 71(4):871-81. PubMed ID: 26682961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The first tigecycline resistant Enterococcus faecium in Norway was related to tigecycline exposure.
    Hegstad K; Pöntinen AK; Bjørnholt JV; Quist-Paulsen E; Sundsfjord A
    J Glob Antimicrob Resist; 2024 Mar; 36():112-115. PubMed ID: 38122982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Nosocomial Cluster of Tigecycline- and Vancomycin-Resistant
    Bender JK; Klare I; Fleige C; Werner G
    Microb Drug Resist; 2020 Jun; 26(6):576-582. PubMed ID: 31895641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tigecycline-based therapy for glycopeptide-resistant Enterococcus faecium infection in a pediatric intensive care unit.
    Trabelsi B; Trifa M; Ben Khalifa S
    Tunis Med; 2016 Jun; 94(6):336-337. PubMed ID: 28051225
    [No Abstract]   [Full Text] [Related]  

  • 8. Characteristic of Enterococcus faecium clinical isolates with quinupristin/dalfopristin resistance in China.
    Wang S; Guo Y; Lv J; Qi X; Li D; Chen Z; Zhang X; Wang L; Yu F
    BMC Microbiol; 2016 Oct; 16(1):246. PubMed ID: 27769188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of a cfr(B) Variant in German Enterococcus faecium Clinical Isolates and the Impact on Linezolid Resistance in Enterococcus spp.
    Bender JK; Fleige C; Klare I; Fiedler S; Mischnik A; Mutters NT; Dingle KE; Werner G
    PLoS One; 2016; 11(11):e0167042. PubMed ID: 27893790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
    Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
    J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin.
    Rathe M; Kristensen L; Ellermann-Eriksen S; Thomsen MK; Schumacher H
    APMIS; 2010 Jan; 118(1):66-73. PubMed ID: 20041873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tigecycline alone and in combination with gentamicin in the treatment of experimental endocarditis due to linezolid-resistant Enterococcus faecium.
    Pontikis K; Pefanis A; Tsaganos T; Tzepi IM; Carrer DP; Giamarellou H
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3392-4. PubMed ID: 23587961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006 to 2010.
    Tsai HY; Liao CH; Chen YH; Lu PL; Huang CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Ko WC; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3402-5. PubMed ID: 22491684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
    Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
    Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms.
    Chen H; Wu W; Ni M; Liu Y; Zhang J; Xia F; He W; Wang Q; Wang Z; Cao B; Wang H
    Int J Antimicrob Agents; 2013 Oct; 42(4):317-21. PubMed ID: 23880167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination.
    Mercier RC; Kennedy C; Meadows C
    Pharmacotherapy; 2002 Dec; 22(12):1517-23. PubMed ID: 12495161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium.
    Abb J
    Int J Antimicrob Agents; 2007 Mar; 29(3):358-60. PubMed ID: 17229553
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduced susceptibility of Enterococcus spp. isolates from Cairo University Hospital to tigecycline: Highlight on the influence of proton pump inhibitors.
    Hassan RM; Ghaith DM; Ismail DK; Zafer MM
    J Glob Antimicrob Resist; 2018 Mar; 12():68-72. PubMed ID: 29274469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010.
    Chen YH; Lu PL; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Ko WC; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1452-7. PubMed ID: 22203598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.